Salt Lake City, UT (PRWEB) May 09, 2013
Academic and industry leaders in gene and cell therapy will be featured at an American Society of Gene & Cell Therapy (ASGCT) Media Event in Salt Lake City, Utah, on Thursday, May 16th, from 9:40 am – 10:20 am, followed immediately by a one-on-one interview session with ASGCT scientists at 10:20 am – 11:45 am. The American Society of Gene and Cell Therapy boasts of a membership consisting of experts bringing clinical breakthroughs to a wide array of diseases and disorders. These advances are positioned to bring meaningful therapies to children and adults, including those suffering from both inherited and acquired illnesses.
The event will profile exciting clinical results reported in patients suffering from serious and often deadly diseases such as liver cancer, ovarian cancer, lymphoma, hemophilia, and many more. For further details, please consider the following examples:
ASGCT scientists will report dramatic results in children and adult patients with Leukemia using gene-modified immune cells that kill tumors specifically while sparing normal tissues in patients. After injected into the blood stream, these cells performed a seek-and-destroy mission of the cancer cells in patients that led to complete remission of their diseases.
Late stage clinical development of live viruses that reproduce only in cancer cells but not normal tissues which, after injection into cancer patients, acted like laser-guided smart bombs that destroyed the tumors without major side effects.
Groundbreaking work will be reported for the orphan disease Aromatic L-Amino Acid Decarboxylase (AADC). This is a progressive fatal disorder whereby children lose all of their motor abilities and die by the age of six years as their parents helplessly stand by. Children who could not sit or control their head movement were treated with gene therapy and have demonstrated remarkable improvement.
Hemophilia researchers have successfully treated men living with this bleeding disorder with gene therapy. These patients, who had spent their entire lives being injected with life-saving clotting factors, have discontinued protein replacement altogether. Investigators have also treated children born with devastating genetic illnesses such as Pompe Disease.
The press event will take place in Room 150ABC in the Salt Palace Convention Center.
Members of the media will also receive complimentary full-access registration to the ASGCT 16th Annual Meeting at the Salt Palace Convention Center. Media representatives who wish to attend may contact ASGCT directly at 414.278.1341 or info(at)asgct(dot)org.
The American Society of Gene & Cell Therapy (ASGCT) is a professional nonprofit medical and scientific organization dedicated to the understanding, development and application of genetic and cellular therapies and the promotion of professional and public education in the field. For more information on ASGCT, visit its website, http://www.asgct.org.